Estimated Vaccination Coverage^ with Individual Vaccines and Vaccination Series Among Children 19-35 Months of Age by Race/Ethnicity* -- US, National Immunization Survey, Q1/2010-Q4/2010†
Vaccine US
National
White only,
non-Hispanic
Black only,
non-Hispanic
HispanicAmerican Indian or
Alaska Native only,
non-Hispanic
Asian only,
non-Hispanic
Native Hawaiian or Other Pacific Islander only,
non-Hispanic
Multiple Race,
non-Hispanic
3+DTaP¥95.0±0.695.1±0.895.3±1.595.1±1.497.3±2.295.7±2.996.9±3.592.4±3.5
4+DTaP‡84.4±1.084.5±1.383.7±2.784.4±2.581.8±7.588.3±4.0NA82.8±4.8
3+Polio§93.3±0.793.2±0.894.0±1.693.8±1.694.6±3.592.8±3.595.1±4.590.2±3.9
1+MMRll91.5±0.790.6±0.992.1±1.992.9±1.693.4±6.391.7±3.696.9±4.089.7±3.8
3+Hib¶90.4±0.990.3±1.289.4±2.392.0±1.793.9±3.085.7±5.793.1±6.487.3±4.4
Hib-PS**92.2±0.892.3±1.190.9±2.293.3±1.595.7±2.789.0±5.394.4±5.890.4±3.8
Hib-FS††66.8±1.367.5±1.665.4±3.464.8±3.177.1±7.469.5±6.8NA70.1±5.8
3+HepB‡‡91.8±0.791.4±0.992.1±1.892.5±1.797.2±2.391.7±3.596.7±3.689.9±3.8
Hep B Birth dose§§64.1±1.363.2±1.664.1±3.665.5±3.171.9±9.662.6±7.2NA64.4±6.4
1+Varllll90.4±0.888.9±1.191.5±2.092.3±1.895.7±2.792.5±3.492.7±6.888.9±3.9
3+PCV¶¶92.6±0.892.8±0.992.6±2.093.4±1.894.5±3.087.8±5.496.7±3.590.6±3.8
4+PCV***83.3±1.084.2±1.279.7±3.083.9±2.385.3±5.078.9±6.0NA83.0±4.7
2+HepA†††49.7±1.445.8±1.648.6±3.757.0±3.1NA50.8±7.5NA49.8±6.6
Rotavirus‡‡‡59.2±1.460.2±1.752.7±3.660.5±3.2NA62.6±7.0NA57.7±6.5
4:3:1§§§82.0±1.181.5±1.381.8±2.882.8±2.581.1±7.585.2±4.4NA81.2±4.9
4:3:1:3llllll78.8±1.278.2±1.578.0±3.080.4±2.679.6±7.677.6±6.1NA78.4±5.1
4:3:1:3-PS¶¶¶80.3±1.179.8±1.579.3±3.081.6±2.680.2±7.680.2±5.9NA80.3±5.0
4:3:1:4-FS****62.2±1.362.5±1.661.0±3.561.0±3.269.8±8.965.4±7.0NA65.6±6.1
4:3:1:3:3:1€74.9±1.273.6±1.574.5±3.177.2±2.777.2±7.874.4±6.3NA75.8±5.3
4:3:1:0:3:1ς77.8±1.176.7±1.477.4±3.079.4±2.778.7±7.781.4±4.8NA78.4±5.1
4:3:1:3:3:1-PS€€76.3±1.275.0±1.575.7±3.178.3±2.777.8±7.876.9±6.0NA77.7±5.1
4:3:1:4:3:1-FSςς59.2±1.359.0±1.658.3±3.658.3±3.267.4±9.062.9±7.1NA63.1±6.1
4:3:1:3:3:1:4€€€70.2±1.369.9±1.666.9±3.472.0±2.973.1±8.167.3±6.7NA73.0±5.4
4:3:1:0:3:1:4ςςς72.7±1.272.7±1.569.3±3.474.1±2.874.5±8.170.2±6.5NA75.6±5.2
4:3:1:3:3:1:4-PS€€€€71.5±1.271.2±1.668.1±3.473.2±2.873.7±8.169.8±6.5NA74.9±5.2
4:3:1:4:3:1:4-FSςςςς56.6±1.356.9±1.654.5±3.655.5±3.264.1±9.259.3±7.2NA61.3±6.2

 
^ Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588 or (CI half width) >10.
Estimates presented as point estimate (%) ± 95% Confidence Interval.
* Self-reported by respondent. Children of Hispanic ethnicity may be of any race.
† Children in the Q1/2010-Q4/2010 National Immunization Survey were born from January 2007 through July 2009.
¥ 3 or more doses of any diphtheria and tetanus toxoids and pertussis vaccines including diphtheria and tetanus toxoids, and any acellular pertussis vaccine (DTaP/DTP/DT).
‡ 4 or more doses of DTaP.
§ 3 or more doses of any poliovirus vaccine.
ll 1 or more doses of measles-mumps-rubella vaccine.
¶ 3 or more doses of Haemophilus influenzae type b (Hib) vaccine.
** Primary series Hib: ≥2 or ≥3 doses of Haemophilus influenzae type b (Hib), depending on brand type.
†† Full series Hib: ≥3 or ≥4 doses of Hib vaccine depending on product type received (includes primary series plus the booster dose).
‡‡ 3 or more doses of hepatitis B vaccine.
§§ 1 or more doses of hepatitis B vaccine administered between birth and age 3 days.
llll 1 or more doses of varicella at or after child's first birthday, unadjusted for history of varicella illness.
¶¶ 3 or more doses of pneumococcal conjugate vaccine (PCV).
*** 4 or more doses of PCV.
††† 2 or more doses of Hepatitis A vaccine.
‡‡‡ ≥2 or ≥3 doses of Rotavirus vaccine, depending on product type received ( ≥2 doses for Rotarix® [RVI] or ≥3 doses for RotaTeq® [RV5]).
§§§ 4 or more doses of DTaP, 3 or more doses of poliovirus vaccine, and 1 or more doses of any MMR vaccine.
llllll 4:3:1 plus 3 or more doses of Hib vaccine of any type.
¶¶¶ 4:3:1 plus the primary series Hib.
**** 4:3:1 plus the full series Hib.
€ 4:3:1 plus 3 or more doses of Hib vaccine of any type, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
ς 4:3:1 plus 3 or more doses of HepB vaccine and 1 or more doses of varicella vaccine. Hib vaccine is excluded.
€€ 4:3:1 plus primary series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
ςς 4:3:1 plus full series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
€€€ 4:3:1 plus ≥3 doses of Hib vaccine of any type, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
ςςς 4:3:1 plus 3 or more doses of HepB vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of PCV. Hib vaccine is excluded.
€€€€ 4:3:1 plus primary series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
ςςςς 4:3:1 plus full series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
tab45_race_nat